Double-blinded, randomized, placebo-controlled trial of the remission inducing and steroid sparing properties of two schedules of ISIS 2302 (ICAM-1 antisense) in active, steroid-dependent crohn's disease
- 30 April 2000
- journal article
- abstracts
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A570
- https://doi.org/10.1016/s0016-5085(00)84415-7
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: